病毒去活化市場規模、佔有率及成長分析（依方法、產品、應用、最終用戶及地區分類）－2026-2033年產業預測

全球病毒去活化市場規模預計在 2024 年達到 6.7646 億美元，從 2025 年的 7.5966 億美元成長到 2033 年的 19.2159 億美元，在預測期（2026-2033 年）內複合年成長率為 12.3%。

全球病毒去活化市場預計將迎來顯著成長，這主要得益於製藥、生物技術和醫療保健產業對高效能病毒去除解決方案日益成長的需求。隨著生物製藥產量的不斷提高，病毒去活化對於去除生物製藥、疫苗和治療產品中的病原體至關重要。市場趨勢凸顯了遵守嚴格監管標準的重要性，迫使企業實施穩健的病毒去活化方法以降低污染風險。生物製造中一次性技術的日益普及提高了生產效率，降低了交叉污染的可能性，並符合病毒風險緩解策略。此外，製藥和生技產業外包模式的興起也提升了受託研究機構（CRO）在病毒去活化服務領域的作用，為市場創新與合作創造了機會。

全球病毒去活化市場促進因素

生物製藥研發，尤其是在單株抗體、基因治療和個人化醫療等領域的日益重視，顯著推動了對高效能病毒去活化技術的需求。隨著先進生物製藥和治療方法的不斷湧現，確保病毒安全性對於維護這些創新治療方法的完整性和安全性至關重要。嚴格的監管合規要求以及對提供高品質、無污染生物製藥的承諾，進一步推動了這項需求的成長。因此，在全球市場格局中，成功的病毒去活化變得愈發重要。

限制全球病毒去活化市場發展的因素

製藥和生物技術產業複雜多變的法規環境為病毒去活化市場帶來了巨大挑戰。企業面臨遵守監管機構複雜要求的艱鉅任務，這些要求往往繁瑣且耗時。為了確保病毒去活化方法的有效性，企業必須進行廣泛的檢驗研究並保存詳盡的文件。這個嚴格的流程通常會導致營運成本增加和時間延長，從而阻礙市場整體效率和發展。因此，如何應對這些監管障礙仍是病毒去活化領域企業面臨的一大阻礙因素。

全球病毒去活化市場趨勢

隨著生物製藥生產的重要性日益凸顯，全球病毒去活化市場正經歷顯著成長。這一快速成長主要得益於複雜生物製藥（包括單株抗體、基因療法和細胞療法）的興起，這些製劑需要嚴格的病毒安全通訊協定。隨著業界不斷採用創新治療方法，強化病毒去活化策略對於確保患者安全和產品完整性至關重要。這一趨勢凸顯了生物製藥領域對先進技術和嚴格監管合規的迫切需求，最終將推動市場擴張，並在不斷變化的治療需求面前建立更具韌性的供應鏈。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球病毒去活化市場規模（依方法及複合年成長率分類）（2026-2033 年）

• 溶劑清潔劑法
• 巴氏殺菌法
• 其他病毒去活化方法

全球病毒去活化市場規模（按產品和複合年成長率分類）（2026-2033 年）

• 試劑盒和試劑
• 服務
• 病毒去活化系統及配件

全球病毒去活化市場規模（按應用及複合年成長率分類）（2026-2033 年）

• 血液和血液製品
• 細胞和基因療法產品
• 幹細胞產品
• 組織和組織產品
• 疫苗和治療

全球病毒去活化市場規模（依最終用戶分類）及複合年成長率（2026-2033 年）

• 製藥和生物技術公司
• 合約研究機構
• 學術研究機構
• 其他最終用戶

全球病毒去活化市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Merck KGaA（Germany）
• Sartorius AG（Germany）
• Charles River Laboratories International, Inc.（United States）
• Parker Hannifin Corporation（United States）
• Thermo Fisher Scientific Inc.（United States）
• Bio-Rad Laboratories, Inc.（United States）
• Mettler-Toledo International Inc.（United States）
• SGS SA（Switzerland）
• WuXi AppTec Co., Ltd.（China）
• Lonza Group AG（Switzerland）
• Pfizer Inc.（United States）
• GE HealthCare Technologies Inc.（United States）
• Danaher Corporation（United States）
• Cerus Corporation（United States）
• Terumo BCT, Inc.（United States）
• Eurofins Scientific SE（Luxembourg）
• Macopharma SA（France）
• Kedrion SpA（Italy）
• Rad Source Technologies, Inc.（United States）

結論與建議

Global Viral Inactivation Market size was valued at USD 676.46 Million in 2024 and is poised to grow from USD 759.66 Million in 2025 to USD 1921.59 Million by 2033, growing at a CAGR of 12.3% during the forecast period (2026-2033).

The global viral inactivation market is set to experience significant growth, fueled by the increasing demand for effective viral clearance solutions across pharmaceuticals, biotechnology, and healthcare sectors. As biopharmaceutical production rises, the necessity for viral inactivation becomes essential in eliminating infectious agents from biological products, vaccines, and therapeutic formulations. Market trends highlight the importance of adhering to strict regulatory standards, compelling companies to implement robust viral inactivation methods to reduce contamination risks. The growing use of single-use technologies in biomanufacturing enhances production efficiency and lowers cross-contamination potential, aligning with viral risk reduction strategies. Additionally, the shift towards outsourcing in the pharmaceutical and biotechnology industries elevates the role of contract research organizations in providing viral inactivation services, creating opportunities for innovation and collaboration within the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Viral Inactivation market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Viral Inactivation Market Segments Analysis

Global Viral Inactivation Market is segmented by Method, Product, Application, End User and region. Based on Method, the market is segmented into Solvent Detergent Method, Pasteurization and Other Viral Inactivation Method. Based on Product, the market is segmented into Kits and Reagents, Services and Viral Inactivation Systems and Accessories. Based on Application, the market is segmented into Blood & Blood Products, Cellular & Gene Therapy Products, Stem Cell Products, Tissue & Tissue Products and Vaccines and Therapeutics. Based on End User, the market is segmented into Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic Research Institutes and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Viral Inactivation Market

The increasing focus on biopharmaceutical research and development, especially within the realms of monoclonal antibodies, gene therapies, and personalized medicine, is significantly fueling the demand for effective viral inactivation techniques. As the creation of sophisticated biologics and advanced therapies continues to expand, ensuring viral safety is essential for preserving the integrity and safety of these innovative treatments. This growing necessity is further driven by the imperative for stringent regulatory adherence and a commitment to delivering high-quality, contaminant-free biopharmaceutical products. Consequently, the emphasis on successful viral inactivation is becoming ever more critical in the global market landscape.

Restraints in the Global Viral Inactivation Market

The complex and constantly changing regulatory environment in the pharmaceutical and biotechnology industries poses significant challenges for the viral inactivation market. Companies face the daunting task of complying with intricate requirements dictated by regulatory bodies, which can be both demanding and lengthy. To ensure that their viral inactivation methods are effective, businesses must undertake extensive validation studies and maintain meticulous documentation. This rigorous process often results in higher operational costs and extended timelines, hindering overall efficiency and progress within the market. Consequently, navigating these regulatory hurdles remains a critical restraint for companies working in the viral inactivation space.

Market Trends of the Global Viral Inactivation Market

The Global Viral Inactivation market is experiencing significant growth due to the escalating prominence of biopharmaceutical manufacturing. This surge is fueled by the rise in complex biologics such as monoclonal antibodies, gene therapies, and cell-based therapies, which require rigorous viral safety protocols. As the industry embraces innovative treatment modalities, enhanced viral inactivation strategies have become critical to ensure patient safety and product integrity. This trend highlights the necessity for advanced technologies and robust regulatory compliance in the biopharmaceutical sector, ultimately driving market expansion and fostering a more resilient supply chain in the face of evolving therapeutic demands.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Viral Inactivation Market Size by Method & CAGR (2026-2033)

• Market Overview
• Solvent Detergent Method
• Pasteurization
• Other Viral Inactivation Method

Global Viral Inactivation Market Size by Product & CAGR (2026-2033)

• Market Overview
• Kits and Reagents
• Services
• Viral Inactivation Systems and Accessories

Global Viral Inactivation Market Size by Application & CAGR (2026-2033)

• Market Overview
• Blood & Blood Products
• Cellular & Gene Therapy Products
• Stem Cell Products
• Tissue & Tissue Products
• Vaccines and Therapeutics

Global Viral Inactivation Market Size by End User & CAGR (2026-2033)

• Market Overview
• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations
• Academic Research Institutes
• Other End Users

Global Viral Inactivation Market Size & CAGR (2026-2033)

• North America (Method, Product, Application, End User)
  • US
  • Canada
• Europe (Method, Product, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Method, Product, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Method, Product, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Method, Product, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sartorius AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories International, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Parker Hannifin Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mettler-Toledo International Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SGS SA (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi AppTec Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE HealthCare Technologies Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cerus Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Terumo BCT, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific SE (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Macopharma SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rad Source Technologies, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations